Jump to content

Deucravacitinib: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
→top: WL
add CA
Line 28: Line 28:
| legal_BR = <!-- OTC, A1, A2, A3, B1, B2, C1, C2, C3, C4, C5, D1, D2, E, F -->
| legal_BR = <!-- OTC, A1, A2, A3, B1, B2, C1, C2, C3, C4, C5, D1, D2, E, F -->
| legal_BR_comment =
| legal_BR_comment =
| legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_CA = Rx-only
| legal_CA_comment = <ref>{{cite web | title=Notice: Multiple Additions to the Prescription Drug List (PDL) [2023-03-08] | website=[[Health Canada]] | date=8 March 2023 | url=https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/prescription-drug-list/notices-changes/mutliple-additions-2023-03-08.html | access-date=21 March 2023}}</ref>
| legal_CA_comment =
| legal_DE = <!-- Anlage I, II, III or Unscheduled -->
| legal_DE = <!-- Anlage I, II, III or Unscheduled -->
| legal_DE_comment =
| legal_DE_comment =

Revision as of 02:47, 22 March 2023

Deucravacitinib
Clinical data
Pronunciation/duːˌkrævəˈsɪtɪnɪb/
doo-KRA-və-SI-ti-nib
Trade namesSotyktu
Other namesBMS-986165
AHFS/Drugs.comMonograph
License data
Pregnancy
category
Routes of
administration		By mouth
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability99%
Protein binding82–90%
MetabolismLiver (primarily CYP1A2)
MetabolitesBMT-153261 (active)
Elimination half-life10 hours
ExcretionFeces, urine
Identifiers
  • 6-(Cyclopropanecarbonylamido)-4-[2-methoxy-3-(1-methyl-1,2,4-triazol-3-yl)anilino]-N- (trideuteriomethyl)pyridazine-3-carboxamide
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
ECHA InfoCard100.329.069 Edit this at Wikidata
Chemical and physical data
FormulaC20H19D3N8O3
Molar mass425.466 g·mol−1
3D model (JSmol)
  • [2H]C([2H])([2H])NC(=O)C1=NN=C(C=C1NC2=CC=CC(=C2OC)C3=NN(C=N3)C)NC(=O)C4CC4
  • InChI=1S/C20H22N8O3/c1-21-20(30)16-14(9-15(25-26-16)24-19(29)11-7-8-11)23-13-6-4-5-12(17(13)31-3)18-22-10-28(2)27-18/h4-6,9-11H,7-8H2,1-3H3,(H,21,30)(H2,23,24,25,29)/i1D3
  • Key:BZZKEPGENYLQSC-FIBGUPNXSA-N

Deucravacitinib, sold under the brand name Sotyktu, is medication used for the treatment of moderate-to-severe plaque psoriasis.[4] It is a tyrosine kinase 2 (TYK2) inhibitor and it is taken by mouth.[4] It was developed by Bristol Myers Squibb.[5]

Deucravacitinib was approved for medical use in the United States in September 2022,[4][6] and in Australia in December 2022.[1] The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.[7]

Medical uses

Deucravacitinib is indicated for the treatment of adults with moderate-to-severe plaque psoriasis.[4]

Mechanism of action

It acts as a highly selective allosteric inhibitor of non-receptor tyrosine-protein kinase 2 (TYK2).[8]

Molecule design

The chemical structure of deucravacitinib contains a methyl amide in which all three hydrogen atoms are replaced by deuterium.[9]

Society and culture

On 26 January 2023, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Sotyktu, intended for the treatment of moderate to severe psoriasis.[10] The applicant for this medicinal product is Bristol-Myers Squibb Pharma EEIG.[10]

References

  1. ^ a b c https://www.tga.gov.au/resources/auspmd/sotyktu
  2. ^ https://www.tga.gov.au/resources/prescription-medicines-registrations/sotyktu-bristol-myers-squibb-australia-pty-ltd
  3. ^ "Notice: Multiple Additions to the Prescription Drug List (PDL) [2023-03-08]". Health Canada. 8 March 2023. Retrieved 21 March 2023.
  4. ^ a b c d e "Sotyktu- deucravacitinib tablet, film coated". DailyMed. 9 September 2022. Archived from the original on 28 September 2022. Retrieved 27 September 2022.
  5. ^ "U.S. Food and Drug Administration Approves Sotyktu (deucravacitinib), Oral Treatment for Adults with Moderate-to-Severe Plaque Psoriasis" (Press release). Bristol Myers Squibb. 10 September 2022. Archived from the original on 10 September 2022. Retrieved 10 September 2022 – via Business Wire.
  6. ^ "Drug Approval Package: Sotyktu". U.S. Food and Drug Administration (FDA). 14 October 2022. Retrieved 4 January 2023.
  7. ^ "Advancing Health Through Innovation: New Drug Therapy Approvals 2022". U.S. Food and Drug Administration (FDA). 10 January 2023. Retrieved 22 January 2023. Public Domain This article incorporates text from this source, which is in the public domain.
  8. ^ Chimalakonda A, Burke J, Cheng L, Catlett I, Tagen M, Zhao Q, et al. (October 2021). "Selectivity Profile of the Tyrosine Kinase 2 Inhibitor Deucravacitinib Compared with Janus Kinase 1/2/3 Inhibitors". Dermatology and Therapy. 11 (5): 1763–1776. doi:10.1007/s13555-021-00596-8. PMC 8484413. PMID 34471993.
  9. ^ Mullard A (September 2022). "First de novo deuterated drug poised for approval". Nature Reviews. Drug Discovery. 21 (9): 623–625. doi:10.1038/d41573-022-00139-6. PMID 35974147. S2CID 251623586.
  10. ^ a b "Sotyktu: Pending EC decision". European Medicines Agency (EMA). 26 January 2023. Retrieved 28 January 2023.


Stub icon

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/enwiki/w/index.php?title=Deucravacitinib&oldid=1145983300"